Abstract
Chronic migraine is defined in different ways. The most commonly used definition is headache on more than 15 days per month in patients with migraine. Chronic migraine is difficult to treat and requires a multidisciplinary approach. Only two pharmacological treatments have been shown to be effective in placebo-controlled randomized trials: topiramate and local injection of botulinum toxin. Both therapies are effective in patients with chronic migraine with and without medication overuse. Many other substances have been investigated in chronic daily headache. All trials were underpowered and, therefore, recommendations concerning possible efficacy are not possible.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 Suppl 1:9–160.
Olesen J, Bousser M, Diener H, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006, 26:742–746.
Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008, 71:1821–1828.
Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010, 30: 599–609.
Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatr. 2010, 81:428–432.
Blumenfeld A, Varon S, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 2010. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20813784 [Accessed October 3, 2010].
• Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008, 71:559–566. This article provides an excellent clinical characterization of chronic migraineurs.
Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788–790.
Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81–89.
Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009, 13:301–307.
Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr. Opin. Neurol. 2009, 22:269–276.
Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008, 48:16–25.
Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006, 46 Suppl 4:S182–191.
•• De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann. Neurol. 2010, 67:325–337. The authors describe a new pathophysiological concept for medication-overuse headache.
De Felice M, Porreca F. Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 2009, 29:1277–1284.
Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007, 7:383–393.
Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006, 29:269–275.
Silvestrini M, Bartolini M, Coccia M, et al. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003, 23:820–824.
Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005, 28:277–279.
Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007, 47:13–21.
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007, 47:170–180.
Diener H, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007,27:814–823.
• Diener H, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009, 29:1021–1027. This is an excellent review on the efficacy of topiramate in patients with chronic migraine with and without medication overuse
Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001, 41:854–861.
Mula M, Viana M, Jauch R, et al. Health-related quality of life measures and psychiatric comorbidity in patients with migraine. Eur. J. Neurol. 2009;16(9):1017–1021.
Silberstein S, Diener H, Lipton R, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008, 48:1087–1095.
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785–793.
Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007, 47:486–499.
Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med. 2007, 8:478–485.
Silberstein SD, Göbel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790–800.
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30:793–803.
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30:804–814.
• Dodick D, Turkel C, DrGryse R, et al. OnabotulinumA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programme. Headache 2010, in press. This article provides pooled PREEMPT study results showing the efficacy of botulinum toxin in chronic migraine treatment.
Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119–128.
Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010, 33:35–39.
Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002, 42:470–482.
Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994, 34:497–502.
Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia 2006, 26:1199–1202.
Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008, 48:1337–1342.
Disclosures
Dr. Hans-Christoph Diener has received grants from the German Research Council, the German Ministry of Education and Science, the European Union, Allergan, Almirall, AstraZeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, and Pfizer; has received consulting fees or honoraria from Addex Pharmaceuticals, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin-Chemie AG, Coherex Medical, CoLucid Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Janssen-Cilag, Minster Pharmaceuticals, MSD Pharmaceuticals, Novartis AG, Johnson & Johnson, Sanofi-Aventis and Medtronic; and has received travel support and fees for participation in review activities (eg, data monitoring boards, statistical analysis, end point committees, etc.) from Addex Pharmaceuticals, Allergan, Almirall, AstraZeneca, Bayer Vital, Coherex Medical, CoLucid Pharmaceuticals, Boehringer Ingelheim, BristolMyersSquibb, GlaxoSmithKline, Janssen-Cilag, MSD Pharmaceuticals, Novartis AG, Johnson & Johnson, Laboratories, Sanofi-Aventis, and Medtronic. Dr. Dagny Holle: none. Dr. David Dodick has served as a consultant for, and has received honoraria from, Boston Scientific, Medtronic, ATI (now Armstrong) Pharmaceuticals, Merck and Co., Pfizer, MAP Pharmaceuticals, NeurAxon, Bristol-Myers-Squibb, Neuralieve, CoLucid, Eli Lilly and Company, Zogenix, and Coherex; has received grants from, or has grants pending with, St. Jude Medical, Medtronic, and Advanced Neurostimulation Systems; has received payment for the development of educational presentations from Miller Medical, the Annenberg Foundation, and IntraMed; and has received travel expense compensation from IntraMed, Coherex, and Neuralieve.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Diener, HC., Holle, D. & Dodick, D. Treatment of Chronic Migraine. Curr Pain Headache Rep 15, 64–69 (2011). https://doi.org/10.1007/s11916-010-0159-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-010-0159-x